Marzo 2017 - Volume XXXVI - numero 3
L'esperienza che insegna
UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna
Indirizzo per corrispondenza: email@example.com
Key words: Asthma, Omalizumab, Severe asthma, Anti-IgE effect, Children
The percentage of asthmatic children with severe asthma is low (< 5%). Children with severe asthma require treatment with high dose of inhaled steroids plus a second controller and/or systemic steroids to control symptoms. They can also remain uncontrolled despite these therapies. Adherence to therapy must always be controlled, especially in case of poor response to therapy and uncontrolled symptoms. Omalizumab is a monoclonal antibody with an anti-IgE effect that could work successfully to control symptoms in selected children with severe asthma. Asthma guidelines consider omalizumab as last therapeutic step in asthmatic children. The paper describes the case of a female paediatric patient with severe asthma treated with omalizumab who had clinical benefits from it and whose medications were gradually reduced and then stopped.
Vuoi citare questo contributo?